April 18, 2016

CHARLOTTESVILLE, VA – BeHealth Solutions, LLC (“BeHealth”) announced today that it has successfully closed on a $2.17 million financing round led by Murray-Bertron of Tampa, FL. The investment enables BeHealth to expand sales, marketing and product development efforts for its flagship product, SHUTi (www.shuti.me) a digital therapeutic for insomnia, and to extend into digital therapeutics that address other highly prevalent and costly health conditions, such as depression, anxiety, PTSD and hypertension. Published data from 5 randomized clinical trials (RCTs) shows that SHUTi users obtain clinically significant improvements in both sleep and depression measures and maintain these improvements at long-term follow up.

SHUTi Logo

BeHealth is expanding access to affordable and effective behavioral health care through the use of scalable and cost-efficient technology. The company licenses SHUTi and other technologies developed by BeHealth’s founders in the University of Virginia Behavioral Health and Technology Lab, and regularly collaborates with top e-health researchers around the world. BeHealth is committed to evidence-based solutions and SHUTi has the most substantial evidence base of any digital therapeutic for insomnia, with over 7 years and $10 million invested in 5 completed RCTs and 6 more ongoing RCT’s.